News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
702 Results
Type
Article (56)
Company Profile (1)
Press Release (645)
Section
Business (253)
Career Advice (1)
Deals (45)
Drug Development (78)
FDA (15)
Job Trends (5)
News (394)
Policy (43)
Tag
Academia (1)
Alliances (64)
Approvals (15)
Bankruptcy (1)
Best Places to Work (1)
Cardiovascular disease (1)
Career advice (1)
Clinical research (75)
Collaboration (3)
COVID-19 (2)
Data (4)
Diabetes (1)
Diagnostics (2)
Earnings (127)
Events (92)
Executive appointments (4)
FDA (17)
Friedreich's ataxia (1)
Funding (2)
Gene editing (1)
Gene therapy (1)
GLP-1 (3)
Government (4)
Healthcare (9)
Infectious disease (2)
IPO (21)
Job creations (4)
Job search strategy (1)
Layoffs (1)
Legal (8)
Medical device (1)
Medtech (1)
Mergers & acquisitions (24)
Metabolic disorders (1)
NextGen: Class of 2026 (4)
Non-profit (1)
Patient recruitment (1)
People (64)
Pharmaceutical (1)
Phase 1 (23)
Phase 2 (24)
Phase 3 (27)
Pipeline (3)
Postmarket research (7)
Preclinical (4)
Rare diseases (13)
Real estate (2)
Regulatory (39)
Startups (2)
Date
Last 30 days (4)
Last 365 days (28)
2026 (4)
2025 (28)
2024 (43)
2023 (77)
2022 (90)
2021 (98)
2020 (91)
2019 (43)
2018 (20)
2017 (31)
2016 (16)
2015 (35)
2014 (27)
2013 (20)
2012 (15)
2011 (14)
2010 (14)
Location
Africa (2)
Asia (147)
Australia (4)
California (11)
Canada (1)
Europe (244)
Georgia (1)
Massachusetts (6)
Nevada (1)
New Jersey (1)
New York (1)
North Carolina (9)
South America (2)
Southern California (10)
United States (29)
702 Results for "chiesi".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Chiesi Global Rare Diseases Reinforces Long-Term Commitment to the Rare Disease Community with Multiple Abstract Presentations at the 22nd Annual WORLDSymposium™
February 5, 2026
·
7 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
February 1, 2026
·
13 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
February 1, 2026
·
9 min read
Mergers & acquisitions
Chiesi, Arbor Weave $2.1B Rare Disease Pact
The centerpiece of the collaboration is the gene editor ABO-101, being developed for primary hyperoxaluria type 1, a rare disease that leads to severe kidney stones.
October 6, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Chiesi Announces FDA Acceptance of New Drug Application for its Triple Combination Inhaler for the Maintenance Treatment of Asthma
October 16, 2025
·
6 min read
Press Releases
Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs
October 6, 2025
·
7 min read
Press Releases
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
November 13, 2025
·
3 min read
Press Releases
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
October 20, 2025
·
11 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
November 3, 2025
·
9 min read
Press Releases
Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025
September 10, 2025
·
3 min read
1 of 71
Next
